Ser Educacional Sa

What it is

Ser Educacional traces its roots to 1993, when Professor José Janguiê Diniz launched the Bureau Jurídico Educational Complex in Recife, running preparatory courses for public-sector exams. A decade later, in 2003, the first degree-granting college — Faculdade Maurício de Nassau — received official accreditation from Brazil’s Ministry of Education.

Today Ser Educacional is one of Brazil’s largest private education groups and the leader by enrolled students in the North and North-east; it serves around 340,000 students across undergraduate, postgraduate, technical and distance-learning programmes in all 26 states and the Federal District. Its portfolio of brands includes UNINASSAU, UNINABUCO, UNG, UNAMA, UNINORTE, UNIFACIMED, UNIJUAZEIRO, UNESC, UNIFASB, UNI7, FAEL, and a string of digital and vocational labels including GOKURSOS, BEDUKA and PROVA FÁCIL.

Who owns it

The company is controlled by its founder, José Janguiê Bezerra Diniz — known simply as “Janguiê” — who serves as founder and chairman of the board. The EODHD data shows institutional investors hold 74.4% of shares, reflecting significant free float, but the Diniz family retains the founding grip through the chair role; the exact family ownership percentage is not disclosed in available public filings.

J.P. Morgan’s affiliated entities raised their stake to 5.06% of outstanding ordinary shares in May 2025.

Ser Educacional listed on B3’s Novo Mercado segment in 2013 — at the time the largest IPO in Latin American education. Novo Mercado is the exchange’s gold-standard governance tier, requiring 100% tag-along rights and a majority of independent board directors.

Who runs it

The chief executive is Jânyo Janguiê Bezerra Diniz — the founder’s son — while the CFO seat is held by João Albérico Porto de Aguiar. José Janguiê Bezerra Diniz chairs the board.

Joaldo Janguiê Bezerra Diniz — another member of the founding family — serves as VP of Services, and Adriano Azevedo holds the COO role. The executive suite is thus a blend of family continuity at the top and professional management beneath it.

The money, in plain words

After two consecutive years of net losses (R$28m (US$5 mn) in 2023, R$1m (US$194 k) in 2024), Ser Educacional posted a clean profit of R$214m (~US$42m) in its fiscal year 2025 — a sharp turnaround. Revenue has grown 21% over two years, from R$1.83bn (US$355 mn) to R$2.22bn (US$431 mn) (our calculation), driven by student intake growth and course-mix improvement.

The company keeps about 11 cents of profit from every real of sales — a net profit margin of 10.9%, healthy for a mass-market education business. For every real shareholders have invested, it earns back roughly 18.5 cents a year — a return on equity of 18.5%, which is solid.

The one genuine concern is the balance sheet: Ser carries net debt of R$1.18bn (~US$229m), nearly equal to its entire market value, so any financing squeeze matters (our calculation).

The market prices the stock at just 1.5 times trailing earnings — a price-to-earnings ratio of 1.5× — which is exceptionally low and implies either deep scepticism about earnings quality or a significant re-rating opportunity. The shares also pay a dividend yield of 4.4%, a meaningful income return at current prices.

What it is doing now

In early 2025 Ser Educacional publicly refreshed its mission, vision and values statement, signalling a strategic pivot toward innovation, entrepreneurship and social impact. The company has been running a share buyback programme approved by the board, using retained earnings to purchase its own stock in the open market.

Management is also expanding medical courses — a high-value segment that commands premium tuition — following regulatory accreditations secured in prior years. Distance learning continues to grow as a share of enrolment, carrying structurally lower costs and supporting margin recovery.

What to watch

• Debt load: Net debt of R$1.18bn (~US$229m) against a R$1.43bn (US$278 mn) market value means refinancing conditions in Brazil’s still-elevated interest-rate environment are a live risk.
• Earnings quality: The P/E of 1.5× is far below sector peers; the market is testing whether the 2025 profit is sustainable or a one-year rebound after two loss years.
• Medical course ramp: New medicine programmes carry high fixed costs upfront; their contribution to revenue in 2026 will be a key growth signal.
• Family succession: With CEO Jânyo Diniz and board chair Janguiê Diniz both from the founding family, governance concentration is a factor for institutional shareholders to monitor.
• Institutional interest: J.P. Morgan’s stake-building in May 2025 may signal renewed buy-side confidence — or simply index-driven flows; direction of travel worth tracking.

This is news, not investment advice.